Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Neuropathy;Peripheral Clinical Trial

Official title: Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Status Recruiting

Clinical Trial Summary

To learn if a process called neuromodulation can help to improve pain due to CIP

Clinical Trial Description

Inclusion Criteria:

• Ability to understand and the willingness to sign a written informed consent document

• Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds

• Patients seen at Pain Management Center at MD Anderson Cancer Center

• Patient ages greater or equal to 18 years but less than or equal to 85 years

Exclusion Criteria:

• Patients with cognitive dysfunction

• Patient with recent history (<6 months) of drug or alcohol abuse

• Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection

• Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy ;

Related Conditions & MeSH terms

• Neuropathy;Peripheral
• Peripheral Nervous System Diseases

• NCT number: NCT06121232
• Study type: Interventional
• Source: M.D. Anderson Cancer Center
• Contact: Saba Javed, M D
• Phone: (713) 792-9530
• Email: sjaved@mdanderson.org
• Status: Recruiting
• Phase: N/A
• Start date: November 2, 2023
• Completion date: April 1, 2026